|
Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (Saesneg) (PDF, 277Kb)
|
|
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in people aged 2 years and older, Policy Position Statement (PP203), July 2024 (Saesneg) (PDF, 388Kb)
|
|
Circumcision for Children, Commissioning Policy, (CP34). December 2024 (Saesneg) (PDF, 344Kb)
|
|
Cleft Lip and/or Palate including Non-Cleft Velopharyngael Dysfuncion: All Ages, Service Specification (CP186), November 2025 (Saesneg) (PDF, 591Kb)
|
|
Corneal cross-linking for keratoconus in children (from birth until their 16th birthday) commissioning policy, (CP271), October 2023 (Saesneg) (PDF, 328Kb)
|
|
Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
|
|
Lumasiran for treating primary hyperoxaluria type 1, Policy Position Statement (PP277), December 2026 (Saesneg) (PDF, 250Kb)
|
|
Nusinersen for treating spinal muscular atrophy, Policy Position Statement (PP191), November 2026 (Saesneg) (PDF, 400Kb)
|
|
Paediatric Endocrinology, Service Specification (CP163), July 2024 (Saesneg) (PDF, 283Kb)
|
|
Paediatric Epilepsy, Commissioning Policy (CP174), September 2022 (Saesneg) (PDF, 487Kb)
|
|
Paediatric Nephrology, Service Specification (CP169), March 2021 (Saesneg) (PDF, 418Kb)
|
|
Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (Saesneg) (PDF, 361Kb)
|
|
Specialised Fetal Medicine, Commissioning Policy, (CP97), October 2023 (Saesneg) (PDF, 372Kb)
|
|
Specialised Paediatric Gastroenterology, Hepatology and Nutrition (PGHAN) (CP211) May 2023 (Saesneg) (PDF, 759Kb)
|
|
Specialised Paediatric Rheumatology Service, Service Specification (CP172), November 2021 (Saesneg) (PDF, 448Kb)
|
|
Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (Saesneg) (PDF, 311Kb)
|